

DATE: September 8, 2003

Sheet 1 of 1

INFORMATION DISCLOSURE STATEMENT

GROUP ART UNIT: Unknown

CLIENT /MATTER: 003/240/SAP

BY APPLICANT

APPLICANT (inventors)
LYON ET AL.EXAMINER
UnknownAPPLICATION NO.
10/057,532FILING DATE
January 25, 2002

U. S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Date Mo./Yr.	Name (Family Name of First Inventor)	Class	Subclass	Filing Date If appropriate
AR	6 1 4 6 6 3 2	11/00				
BR						
CR						
DR						
ER						
FR						

RECEIVED

SEP 11 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	Document Number	Date Mo./Yr.	Country	English Abstract		Class	Subclass	Translation Available	
				Enclosed	No			Enclosed	No
GR	WO 9 7 3 0 1 5 9	08/97	France	Yes					
HR	WO 9 6 3 3 7 3 9	10/96	Belgium	Yes				Enclosed	
IR	WC 0 0 2 3 1 0 5	04/00	Belgium	Yes				Enclosed	
JR	WO 0 1 0 0 2 3 1	01/01	Belgium	Yes				Enclosed	
NR									

OTHER DOCUMENTS (Including in this order, Author, Title, Periodical Name, Date, Pertinent Pages, Etc.)

QR	Angov et al. (1999) Process development for clinical grade Plasmodium falciparum MSP1/42(3D7) expressed in E. coli. American Journal of Tropical Medicine and Hygiene, 61 p. 207 (48th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, D.C. 28 November - 2 December 1999, Abstract 133).
RR	Kumar et al. (1995) Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein -1 in Aotus monkeys. Molecular Medicine 1, 325-332.
SR	Chang et al. (1996) A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein-1 protects Aotus monkeys against malaria. Infection and Immunity 64, 253-261.
TR	
UR	
VR	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SAP-1449 1/97

BEST AVAILABLE COPY